Pazopanib

Introduction Overview

Generic Name

pazopanib

Brand Name

Votrient

Dosage Form

oral tablet

Drug Class

VEGF/VEGFR inhibitors

Pharmacokinetics

Absorption:
Pazopanib is administered orally, with bioavailability influenced significantly by food intake; it is recommended to take Votrient on an empty stomach — at least 1 hour before or 2 hours after a meal — to optimize absorption and reduce variability. The drug demonstrates moderate to high absorption with peak plasma concentrations achieved approximately 2 to 4 hours post-dose. The absorption can be affected by gastric pH altering agents such as antacids and proton pump inhibitors, which can decrease its solubility and systemic exposure, thus requiring careful timing or avoidance during treatment.

Distribution:
Pazopanib exhibits high plasma protein binding (>99%) primarily to albumin, which may influence its pharmacodynamics. The volume of distribution suggests extensive tissue distribution. Pazopanib penetrates various tissues and interacts with the vascular endothelial growth factor receptors in endothelium and tumor sites. Although detailed tissue distribution studies in humans are limited, animal models suggest preferential accumulation in sites of active angiogenesis.

Metabolism:
Metabolism of pazopanib occurs predominantly via hepatic cytochrome P450 enzymes, mainly CYP3A4, with minor contributions from CYP1A2 and CYP2C8. It undergoes oxidative metabolism producing inactive metabolites. The metabolic pathway highlights the importance of liver function in pazopanib clearance, and drugs that inhibit or induce CYP3A4 can significantly affect pazopanib plasma concentrations. Genetic polymorphisms affecting these enzymes could also influence individual response and toxicity.

Elimination:
The elimination half-life of pazopanib is approximately 31 hours, allowing once-daily dosing. The drug and its metabolites are primarily excreted through feces, with minimal renal excretion, making it suitable for patients with mild to moderate renal impairment. Steady-state concentrations are usually achieved within 7 to 14 days of daily dosing. Due to this elimination profile, dose adjustments are typically not required for renal insufficiency but must be monitored carefully in hepatic impairment, which can significantly reduce drug clearance and increase toxicity risks.

Dosage Forms

Available Dosage Forms:
Votrient is available as oral tablets formulated for once-daily oral administration. Each tablet contains 200 mg of the active ingredient pazopanib.

Dosages for Adults and Adolescents:
The standard recommended dose for adults with advanced renal cell carcinoma or soft tissue sarcoma is 800 mg taken orally once daily on an empty stomach (at least 1 hour before or 2 hours after meals). Tablets must be swallowed whole with water and should not be broken, crushed, or chewed to avoid alterations in absorption kinetics. Missed doses should be administered as soon as possible unless less than 12 hours remain before the next dose, in which case the dose should be skipped.

Specific Patient Populations:
Special caution is advised in patients with hepatic impairment due to the potential for increased systemic exposure and higher risk of severe hepatotoxicity; these patients should undergo frequent liver function monitoring. Votrient is contraindicated in patients with severe liver disease. There is no significant dosage adjustment required for mild to moderate renal impairment. It is not recommended during pregnancy due to teratogenic potential, and strict contraception is advised for patients of reproductive potential. The drug is also contraindicated during breastfeeding. Additionally, the use of Votrient should be withheld at least 7 days prior to scheduled surgeries due to increased bleeding risk.

Mechanism Of Action

Pazopanib, the active compound in Votrient, is a potent oral tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), fibroblast growth factor receptor (FGFR), and c-KIT. By inhibiting these receptor tyrosine kinases, pazopanib disrupts critical signaling pathways responsible for angiogenesis, the process by which tumors develop new blood vessels to sustain their growth and metastasis.

At the molecular level, pazopanib competitively binds to the ATP-binding site of the receptor tyrosine kinases, preventing autophosphorylation and subsequent activation of downstream signaling cascades such as the MAPK and PI3K/AKT pathways. This inhibition leads to reduced endothelial cell proliferation, migration, and survival, ultimately limiting tumor vascularization and growth. Additionally, it impacts tumor cells expressing c-KIT, thus exerting a direct antiproliferative effect on certain cancer types.

Clinically, this mechanism translates into slowed tumor progression and, in some patients, tumor shrinkage, particularly in advanced renal cell carcinoma and soft tissue sarcomas. Comparative studies highlight that pazopanib, unlike conventional cytotoxic chemotherapy, offers a targeted approach with a more favorable side effect profile, promoting antiangiogenic activity without causing widespread cytotoxic damage.

Extensive clinical trials and research data support the efficacy of pazopanib, illustrating significant prolongation of progression-free survival and tumor response rates in patients treated with this agent. The drug’s targeted mechanism has positioned it as a valuable therapeutic option in oncology, complementing or serving as an alternative to traditional chemotherapy and immunotherapy.

Pharmacological Actions

Inhibition of VEGF receptor-mediated angiogenesis, preventing new blood vessel formation essential for tumor growth.
Blockade of PDGF receptors affecting pericyte function and tumor microenvironment stabilization.
Suppression of FGFR signaling, contributing to antiangiogenic and antitumor effects.
Inhibition of c-KIT tyrosine kinase activity, potentially limiting proliferation in tumors expressing this receptor.
Reduction of endothelial cell proliferation, migration, and survival within tumor vasculature.
Anti-proliferative effects on cancer cells via disruption of growth factor signaling pathways.
Promotion of tumor dormancy by limiting vascular supply and nutrient access.
Exertion of anti-metastatic properties through impairment of vascular support to secondary tumor sites.
Improvement of progression-free survival in patients with advanced renal cell carcinoma and soft tissue sarcoma.
Targeted therapy approach minimizing damage to normal cells compared to conventional chemotherapy.
Potential to modify tumor microenvironment making it less conducive for cancer progression.
Synergistic effects with other anticancer agents due to its antiangiogenic properties.
Dose-dependent pharmacodynamics linked to plasma concentration and VEGFR inhibition levels.
Ability to cross-react with multiple tyrosine kinases, providing a broad mechanism to inhibit tumor growth.

Therapeutic Or Clinical Uses

Treatment of advanced renal cell carcinoma (kidney cancer) in adult patients.
Management of advanced soft tissue sarcoma (STS) in adult patients after prior chemotherapy.
Utilization as second-line therapy in patients with progressive disease unresponsive to other treatments.
Off-label potential in tumors exhibiting VEGF/VEGFR pathway dependence.
Provision of targeted antiangiogenic therapy as a well-tolerated oral agent.
Improvement of progression-free survival and disease stabilization in metastatic cancers.
Use in patients unsuitable for or resistant to traditional chemotherapeutic regimens.
Therapy option for sarcoma types other than adipocytic soft tissue sarcoma or gastrointestinal stromal tumors.
Reducing tumor vascularization to slow tumor progression and metastatic potential.
Adjunctive agent in multidisciplinary cancer management strategies.
Facilitation of oral administration allowing outpatient treatment and improved patient quality of life.
Treatment modality for patients with specific molecular tumor profiles sensitive to VEGFR inhibition.
Option for patients who require once-daily dosing due to pharmacokinetic properties.
Therapeutic alternative for patients with contraindications to other kinase inhibitors.

Side Or Adverse Effects

Severe or life-threatening hepatotoxicity characterized by nausea, vomiting, upper abdominal pain, jaundice, and elevated liver enzymes.
Hypertension, including risk of dangerously high blood pressure requiring monitoring and management.
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain.
Hematologic toxicity including lowered blood cell counts causing increased risk of infections and bleeding.
Cardiac adverse effects including heart failure, arrhythmias, and palpitations.
Signs of bleeding or bruising due to impairment of blood clotting mechanisms.
Delayed wound healing and increased risk of wound complications post-surgery.
Fatigue, headache, and dizziness which may impact patient quality of life.
Tumor pain, bone pain, and muscle pain potentially related to tumor response or drug effects.
Respiratory difficulties such as dyspnea or cough associated with pulmonary toxicity.
Changes in hair color and skin pigmentation as dermatological side effects.
Altered taste sensation leading to decreased appetite and weight loss.
Immune-related reactions including rare hypersensitivity and allergic responses.
Risk of gastrointestinal perforation or fistula formation, especially in patients with prior GI disorders or surgery.
Increased susceptibility to infections presenting with fever, sore throat, and other systemic symptoms.

Precautions

Conduct baseline and frequent liver function tests due to potential for severe hepatotoxicity during treatment.
Monitor blood pressure regularly and manage hypertension aggressively to avoid cardiovascular complications.
Assess complete blood counts periodically to detect and manage hematologic toxicities promptly.
Perform cardiac evaluation before and during treatment in patients with pre-existing heart disease or risk factors.
Avoid concomitant use of grapefruit or grapefruit juice as it can increase pazopanib plasma levels causing toxicity.
Instruct patients to report any signs of bleeding, bruising, or infection immediately.
Employ effective contraception during treatment and for at least two weeks after discontinuation due to teratogenic risk.
Refrain from breastfeeding during therapy and for two weeks after cessation.
Hold therapy prior to surgery (at least 7 days) to reduce risk of bleeding and poor wound healing.
Avoid concurrent use of proton pump inhibitors and antacids within several hours of dosing to ensure adequate drug absorption.
Evaluate thyroid function periodically as pazopanib can cause hypothyroidism.
Strictly avoid use in patients with severe hepatic impairment.
Carefully monitor neurological status for headaches, seizures, or vision changes which may indicate serious adverse events.
Advise dose modification or interruption based on severity of adverse reactions according to clinical guidelines.
Educate patients on promptly reporting symptoms suggestive of cardiac ischemia, stroke, or tumor lysis syndrome.

Warnings

Severe and potentially fatal liver injury can occur; regular monitoring of liver enzymes and bilirubin is mandatory.
Black box warning regarding hepatotoxicity necessitates immediate drug discontinuation if significant liver injury is suspected.
Risk of severe hypertension which may lead to hypertensive crisis if untreated.
Potential for QT interval prolongation and serious cardiac arrhythmias; avoid in patients with long QT syndrome.
Increased risk of bleeding and hemorrhage; caution in patients with bleeding disorders or on anticoagulants.
Possibility of gastrointestinal perforation and fistula formation, particularly in patients with prior abdominal surgery or radiation.
Not recommended during pregnancy due to teratogenicity and risk of fetal harm.
Risk of impaired wound healing and complications post-surgery requiring temporary drug discontinuation.
May cause severe infections due to neutropenia; immediate evaluation and management are essential.
Drug interactions may enhance toxicity; particularly avoid strong CYP3A4 inhibitors or inducers.
Avoid abrupt discontinuation without physician guidance to prevent adverse outcomes.
Use with extreme caution in elderly patients due to increased susceptibility to hepatic toxicity.
Careful assessment of cardiac and liver function is essential before and during therapy.
Patients should be closely observed for signs of tumor lysis syndrome, especially during initial treatment.
Hypothyroidism or other endocrine abnormalities can occur requiring clinical monitoring.

Contraindication

Known hypersensitivity to pazopanib or any formulation components.
Severe hepatic impairment due to increased risk of life-threatening hepatotoxicity.
Pregnancy, as Votrient is teratogenic and may cause fetal harm.
Breastfeeding during treatment and for two weeks after cessation.
Concurrent use with strong CYP3A4 inhibitors or inducers without close monitoring due to risk of toxicities or reduced efficacy.
Patients with uncontrolled hypertension or significant cardiac disease without adequate stabilization.
Previous or current gastrointestinal perforation or fistula related to prior therapy or disease.
Active bleeding or hemorrhagic disorders not controlled prior to initiation.
Recent major surgery until full recovery and adequate wound healing.
Use in pediatric patients due to lack of established safety and efficacy.
Severe uncontrolled infections or immunocompromised status.
Concurrent use of drugs that significantly increase gastric pH interfering with absorption, unless managed appropriately.
Individuals with long QT syndrome or history of torsades de pointes.
Patients unable to comply with frequent laboratory monitoring requirements.
Known interactions with other critical medications that cannot be safely managed or avoided.

Drug Interactions

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase pazopanib plasma levels leading to enhanced toxicity.
CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease pazopanib effectiveness by lowering plasma concentrations.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and can increase systemic exposure of pazopanib.
Co-administration with anticoagulants may increase bleeding risk due to pazopanib’s effects on platelet function and vasculature.
Statins such as simvastatin may have altered metabolism; caution is advised as pazopanib may increase statin levels increasing risk of myopathy.
Heart rhythm medications that prolong QT interval may potentiate cardiac arrhythmias when taken with pazopanib.
Certain antidepressants metabolized by CYP pathways may have altered levels, necessitating monitoring for efficacy and toxicity.
HIV or AIDS medications, especially protease inhibitors, can modify pazopanib metabolism and pharmacokinetics.
Stomach acid reducers (proton pump inhibitors, H2 blockers) and antacids can reduce pazopanib absorption and plasma concentration.
Antibiotics that inhibit CYP enzymes may elevate pazopanib levels requiring dose adjustments.
Herbal supplements such as St. John’s Wort, a CYP3A4 inducer, should be avoided for decreased efficacy.
Co-administration with other VEGFR inhibitors or antiangiogenic agents can amplify toxicity and adverse effects.
Drugs affecting platelet aggregation or endothelial function may enhance bleeding risk when combined with pazopanib.
Concomitant use with strong inhibitors or inducers of UGT1A1 enzyme may also impact pazopanib metabolism.
Interactions with agents that prolong bleeding time or interfere with coagulation pathways require clinical vigilance.

Preparations Of The Drug

Votrient is formulated as an oral tablet containing 200 mg of pazopanib hydrochloride.
Available exclusively as film-coated tablets designed for oral administration.
Tablets must be swallowed whole with water and should not be split, crushed, or chewed.
Supplied in blister packs or bottles according to prescribing specifications.
Storage conditions require room temperature maintenance, protected from moisture and heat.
No intravenous or alternative administration routes are currently available.
No available liquid or pediatric formulations.
Each tablet contains inactive excipients to aid in stability, absorption, and patient tolerability.
Generic formulations contain the same active ingredient and must meet identical bioequivalence standards.
Packaging includes patient information leaflets focusing on dosing, precautions, and side effects.
Prescribing information mandates specific guidelines for dose administration with emphasis on fasting state.
No known extended-release or slow-release formulations exist for pazopanib.
Preparation does not require any compounding or special preparation prior to administration.
Medicinal product is intended for chronic oral therapy as directed by oncology specialists.
Careful labelling and patient education materials accompany the drug to optimize adherence and safety.